We selected MDA-MB-231 breast cancer cell line because it similarly expresses YAP and TAZ co-activators, presents a high TEAD transcriptional activity [21] and yields a high expression of gene targets (AXL, Cyr61 and CTGF) [21,22]. The gene discussed is CCN1; the disease is breast carcinoma.